An open-label pilot trial of faecal microbiome transfer to restore the gut microbiome in anorexia nervosa: protocol

被引:2
|
作者
Wilson, Brooke C. [1 ]
Derraik, Jose G. B. [1 ,2 ]
Albert, Benjamin B. [1 ]
Leong, Karen S. W. [1 ]
Tweedie-Cullen, Ry Y. [1 ]
Creagh, Christine [1 ]
Depczynski, Marysia [1 ]
Edwards, Taygen [1 ]
Vatanen, Tommi [1 ,3 ]
Thabrew, Hiran [4 ,5 ]
Cutfield, Wayne S. [1 ]
O'Sullivan, Justin M. [1 ]
机构
[1] Univ Auckland, Liggins Inst, Auckland, New Zealand
[2] Univ Auckland, Fac Med & Hlth Sci, Dept Paediat Child & Youth Hlth, Auckland, New Zealand
[3] Univ Helsinki, Helsinki Inst Life Sci, Helsinki, Finland
[4] Univ Auckland, Dept Psychol Med, Auckland, New Zealand
[5] Univ Auckland, Ctr Infant Child & Adolescent Mental Hlth, Te Ara Haro, Auckland, New Zealand
来源
BMJ OPEN | 2023年 / 13卷 / 07期
关键词
eating disorders; microbiology; therapeutics; transplant medicine; gastroenterology; INTESTINAL MICROBIOTA; INSULIN SENSITIVITY; EATING-DISORDERS; TRANSPLANTATION; ANXIETY; PERMEABILITY; INDIVIDUALS; DEPRESSION;
D O I
10.1136/bmjopen-2022-070616
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionIndividuals with anorexia nervosa (AN) harbour distinct gut microbiomes compared with healthy individuals, which are sufficient to induce weight loss and anxiety-like behaviours when transplanted into germ-free mice. We hypothesise that faecal microbiome transfer (FMT) from healthy donors would help restore the gut microbiome of individuals with AN, which in turn, may aid patient recovery. MethodsWe aim to conduct an open-label pilot study in 20 females aged 16-32 years in Auckland, New Zealand who meet the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) criteria for AN and have a body mass index 13-19 kg/m(2). We will recruit four healthy, lean, female donors, aged 18-32 years, who will undergo extensive clinical screening prior to stool donation. Faecal microbiota will be harvested from donors and double encapsulated in delayed release, acid-resistant capsules. All participants will receive a single course of 20 FMT capsules (five from each donor) which they can choose to take over two or four consecutive days. Stool and blood samples will be collected from participants over a period of 3 months to assess their gut microbiome profile, metabolome, levels of intestinal inflammation and nutritional status. Our primary outcome is a shift in the gut microbiome composition at 3 weeks post-FMT (Bray-Curtis dissimilarity). We will also monitor participants' body composition (whole-body dual-energy X-ray absorptiometry scans), eating disorder psychopathology, mental health and assess their views on, and tolerability of, treatment. All adverse events will be recorded and reviewed by an independent data monitoring committee. Ethics and disseminationEthics approval was provided by the Central Health and Disability Ethics Committee (Ministry of Health, New Zealand, 21/CEN/212). Results will be published in peer-reviewed journals and presented to both scientific and consumer group audiences.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Longitudinal analysis of the gut microbiome in adolescent patients with anorexia nervosa: microbiome-related factors associated with clinical outcome
    Andreani, Nadia Andrea
    Sharma, Arunabh
    Dahmen, Brigitte
    Specht, Hannah E.
    Mannig, Nina
    Ruan, Vanessa
    Keller, Lara
    Baines, John F.
    Herpertz-Dahlmann, Beate
    Dempfle, Astrid
    Seitz, Jochen
    GUT MICROBES, 2024, 16 (01)
  • [22] Randomized Open-Label Pilot Study of the Influence of Probiotics and the Gut Microbiome on Toxic Metal Levels in Tanzanian Pregnant Women and School Children
    Bisanz, Jordan E.
    Enos, Megan K.
    Mwanga, Joseph R.
    Changalucha, John
    Burton, Jeremy P.
    Gloor, Gregory B.
    Reid, Gregor
    MBIO, 2014, 5 (05):
  • [23] Gut microbiome-brain interactions in anorexia nervosa: Potential mechanisms and regulatory strategies
    Zhu, Ran
    Tian, Peijun
    Zhang, Hao
    Wang, Gang
    Chen, Wei
    NEUROPHARMACOLOGY, 2023, 224
  • [24] Novel ketamine and zinc treatment for anorexia nervosa and the potential beneficial interactions with the gut microbiome
    Elwyn, Rosiel
    Mitchell, Jules
    Kohn, Michael R.
    Driver, Christina
    Hay, Phillipa
    Lagopoulos, Jim
    Hermens, Daniel F.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2023, 148
  • [25] The Gut Microbiome and Metabolomics Profiles of Restricting and Binge-Purging Type Anorexia Nervosa
    Monteleone, Alessio Maria
    Troisi, Jacopo
    Serena, Gloria
    Fasano, Alessio
    Dalle Grave, Riccardo
    Cascino, Giammarco
    Marciello, Francesca
    Calugi, Simona
    Scala, Giovanni
    Corrivetti, Giulio
    Monteleone, Palmiero
    NUTRIENTS, 2021, 13 (02) : 1 - 13
  • [26] Quetiapine in anorexia nervosa patients: An open label outpatient pilot study
    Powers, Pauline S.
    Bannon, Yvonne
    Eubanks, Rebecca
    McCormick, Terry
    INTERNATIONAL JOURNAL OF EATING DISORDERS, 2007, 40 (01) : 21 - 26
  • [27] The effects of probiotics administration on the gut microbiome in adolescents with anorexia nervosa-A study protocol for a longitudinal, double-blind, randomized, placebo-controlled trial
    Groebner, Eva-Maria
    Zeiler, Michael
    Fischmeister, Florian Ph S.
    Kollndorfer, Kathrin
    Schmelz, Sonja
    Schneider, Andrea
    Haid-Stecher, Nina
    Sevecke, Kathrin
    Wagner, Gudrun
    Keller, Lara
    Adan, Roger
    Danner, Unna
    Elburg, Annemarie
    Vijgh, Benny
    Kooij, Karlijn Liselotte
    Fetissov, Serguei
    Andreani, Nadia A.
    Baines, John F.
    Dempfle, Astrid
    Seitz, Jochen
    Herpertz-Dahlmann, Beate
    Karwautz, Andreas
    EUROPEAN EATING DISORDERS REVIEW, 2022, 30 (01) : 61 - 74
  • [28] N-acetylcysteine in bulimia nervosa - Open-label trial
    Guerdjikova, Anna I.
    Blom, Thomas J.
    Mori, Nicole
    McElroy, Susan L.
    EATING BEHAVIORS, 2013, 14 (01) : 87 - 89
  • [29] Zonisamide in the Treatment of Bulimia Nervosa: An Open-Label, Pilot, Prospective Study
    Guerdjikova, Anna I.
    Blom, Thomas J.
    Martens, Brian E.
    Keck, Paul E., Jr.
    McElroy, Susan L.
    INTERNATIONAL JOURNAL OF EATING DISORDERS, 2013, 46 (07) : 747 - 750
  • [30] SIM01 as a novel microbiome replacement therapy for COVID-19: An open-label pilot study
    Zhang, L.
    Xu, Z.
    Mak, J. W. Y.
    Chan, F. K. L.
    Ng, S. C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 272 - 272